BMY
NYSE · Pharmaceuticals
Bristol-Myers Squibb Co
$55.53
+0.83 (+1.52%)
BMY News19 articles
Amazon Ousts Walmart to Top Fortune 500, Reshaping Corporate Peeking Order
Amazon has claimed the top spot on the 2026 Fortune 500, ending Walmart's 13-year run and signaling a shift in corporate power driven by e-commerce, cloud computing, and healthcare.
Amazon Ousts Walmart as Fortune 500 Leader; Regional Giants Shine
Amazon unseats Walmart as Fortune 500 No. 1, breaking a 13-year streak. Erie Insurance rises, New Jersey boasts 15 firms, and New England has over 20 companies on the list.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Pfizer's Cancer Pipeline Takes Center Stage After ASCO Data Dump
Pfizer enters Monday's trading with a wealth of new cancer drug data from ASCO and a $10.5B China partnership, positioning the stock for a potential re-rating.
Replimune Surges 85% on FDA Priority Review for Melanoma Drug
Replimune shares soared 85% after the FDA agreed to a priority review for its melanoma drug RP1, following a previous rejection. New trial data is expected soon.
Regeneron Plunges 10% on Melanoma Drug Trial Failure
Regeneron Pharmaceuticals shares dropped 9.8% Monday after its late-stage melanoma drug trial with fianlimab failed to meet its primary endpoint, missing statistical significance versus Merck's Keytruda.
Wall Street Slips as Tech Retreats, Bond Yields Stay Elevated
U.S. stocks declined Monday as technology shares lost momentum ahead of Nvidia's earnings, while rising oil and elevated bond yields kept inflation concerns in focus.
Regeneron Shares Slide After Melanoma Combo Misses Key Goal
Regeneron shares tumbled 11.8% in premarket trading after its melanoma drug combo missed statistical significance on progression-free survival versus Keytruda.
Pfizer Faces Investor Scrutiny After Weekly Decline Amid Pipeline Concerns
Pfizer shares dropped 1.63% on Friday to $25.33, lagging the S&P 500. Despite a 5% revenue increase and reaffirmed 2026 guidance, investor caution persists over pipeline risks and competitive pressure from Eli Lilly.
Pfizer Q1 Beats Estimates, Patent Cliff Concerns Linger
Pfizer reported Q1 adjusted EPS of $0.75 on $14.45B revenue, beating estimates. Growth in Eliquis and Padcev offset COVID declines, but patent cliff remains a key concern.
Lilly's $7B Kelonia Buy Targets In Vivo CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal worth up to $7 billion, gaining an in vivo CAR-T therapy currently in Phase 1 trials for multiple myeloma.
Lilly Acquires Kelonia in $7B Bet on In-Body CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal valued at up to $7 billion, gaining an experimental in-body CAR-T therapy for blood cancer. Lilly shares rose 2.5% on the news.
J&J Q1 Earnings Surpass Expectations, Lifts 2026 Forecast
Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.
Merck's $6.7B Terns Buyout Anchors Stock Near Offer Price
Merck has agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal. Terns shares traded at $52.86, close to Merck's $53-per-share offer, as investors weigh the deal's completion.
Pfizer Shares Dip as GSK RSV Vaccine Gains Ground, Eliquis Data Provides Support
Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.
J&J Seeks Earlier Use of Tecvayli in Europe Following US Myeloma Approval
Johnson & Johnson has submitted an application to European regulators to expand the use of its myeloma drug Tecvayli as a monotherapy after just one prior treatment. This follows recent U.S. approval for a Tecvayli combination and is supported by trial data showing a 71% reduction in disease progression risk.
Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting
Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.
Eli Lilly shares retreat as $2.4B Orna acquisition and China partnership draw scrutiny
Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.
Eli Lilly Shares Dip Following $2.4 Billion Orna Therapeutics Acquisition Announcement
Eli Lilly shares declined 1.3% in after-hours trading after announcing a $2.4 billion acquisition of Orna Therapeutics. Investors are monitoring the deal's impact on Lilly's pipeline and upcoming regulatory decisions.